These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 27693013

  • 21. Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
    Cheng L, Nelson BC, Mehta M, Seval N, Park S, Giddins MJ, Shi Q, Whittier S, Gomez-Simmonds A, Uhlemann AC.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320724
    [Abstract] [Full Text] [Related]

  • 22. Comparative effectiveness of cefmetazole versus carbapenems and piperacillin/tazobactam as initial therapy for bacteremic acute cholangitis: A retrospective study.
    Aoto K, Inose R, Kosaka T, Shikata K, Muraki Y.
    J Infect Chemother; 2024 Mar; 30(3):213-218. PubMed ID: 37832824
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H, Tomini E, Emirian A, Join-Lambert O, Lécuyer H, Zahar JR, Jullien V.
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam.
    Namikawa H, Yamada K, Yamairi K, Shibata W, Fujimoto H, Takizawa E, Niki M, Nakaie K, Oinuma KI, Niki M, Takemoto Y, Kaneko Y, Shuto T, Kakeya H.
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):287-292. PubMed ID: 31005401
    [Abstract] [Full Text] [Related]

  • 30. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W.
    BMC Infect Dis; 2017 Jun 07; 17(1):404. PubMed ID: 28592240
    [Abstract] [Full Text] [Related]

  • 31. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS, Moland ES.
    Antimicrob Agents Chemother; 2001 Dec 07; 45(12):3548-54. PubMed ID: 11709338
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH, Lee NR, Joo EJ, Moon SY, Choi JK, Park DA, Peck KR.
    Eur J Clin Microbiol Infect Dis; 2018 Feb 07; 37(2):305-311. PubMed ID: 29177611
    [Abstract] [Full Text] [Related]

  • 35. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.
    Retamar P, López-Cerero L, Muniain MA, Pascual Á, Rodríguez-Baño J, ESBL-REIPI/GEIH Group.
    Antimicrob Agents Chemother; 2013 Jul 07; 57(7):3402-4. PubMed ID: 23612190
    [Abstract] [Full Text] [Related]

  • 36. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW.
    Clin Infect Dis; 2008 Mar 15; 46(6):862-7. PubMed ID: 18279040
    [Abstract] [Full Text] [Related]

  • 37. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM, Askin G, Christos P.
    Int J Antimicrob Agents; 2018 Nov 15; 52(5):554-570. PubMed ID: 30081138
    [Abstract] [Full Text] [Related]

  • 38. [Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients].
    Sudo F, Ishiwada N, Hoshino T, Fukasawa C, Inami Y, Hishiki H, Takeda N, Kurosaki T, Kohno Y.
    Kansenshogaku Zasshi; 2005 Sep 15; 79(9):637-43. PubMed ID: 16248372
    [Abstract] [Full Text] [Related]

  • 39. Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?
    Perez F, Bonomo RA.
    Clin Infect Dis; 2015 May 01; 60(9):1326-9. PubMed ID: 25586684
    [No Abstract] [Full Text] [Related]

  • 40. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
    Rodríguez-Baño J, Navarro MD, Retamar P, Picón E, Pascual Á, Extended-Spectrum Beta-Lactamases–Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group.
    Clin Infect Dis; 2012 Jan 15; 54(2):167-74. PubMed ID: 22057701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.